Compare BridgeBio Pharma Inc (BBIO) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Vanguard S&P 500 Growth Index Fund ETF trades at $85. The key difference: Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | VOOG | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.17 | $85.42 |
52-Week Low | $47.29 | $65.32 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
VOOG, the Vanguard S&P 500 Growth ETF, trades at $85.42, up 0.68% on the day and near a 52-week high. Technical indicators show a bullish trend with strong moving average support, though the 6-day RSI suggests overbought conditions. Recent news highlights institutional accumulation, such as Apella Capital increasing its stake by 463.2% in Q2 2026, and positive coverage from financial outlets comparing its low expense ratio and growth focus favorably against peers.
The outlook for VOOG remains positive, driven by exposure to large-cap growth stocks and strong institutional interest. Key risks include high concentration in technology sectors, making it vulnerable to sector-specific downturns, and broader market volatility. Its low expense ratio of 0.07% and historical outperformance present a compelling case for growth-oriented investors, but caution is warranted given elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
